US Patent 9221814 Heterocyclic guanidine F
Patent 9221814 was granted and assigned to Lycera on December, 2015 by the United States Patent and Trademark Office.
All edits
Edits on 3 Dec, 2023
Golden AI
Edits made to:
Article (+263 characters)
Article
Patent abstract
The invention provides heterocyclic guanidine compounds that inhibit F1F0-ATPase, and methods of using heterocyclic guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
Edits on 13 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09221814 Heterocyclic guanidine F US Patent 9221814 Heterocyclic guanidine F
Infobox
Patent Number
0922181400
Patent Number
922181400
Edits on 22 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 23 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
092218140
Date of Patent
December 29, 2015
0Patent Application Number
144037870
Date Filed
June 7, 2013
0Official Website
Patent Primary Examiner
Edits on 24 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
092218140
Date of Patent
December 29, 2015
0Patent Application Number
144037870
Date Filed
June 7, 2013
0Official Website
Patent Primary Examiner
Edits on 17 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 4 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09221814 Heterocyclic guanidine F
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09221814
Date of patent
December 29, 2015
Patent application number
14403787
Date Filed
June 7, 2013
Patent primary examiner
Find more entities like US Patent 9221814 Heterocyclic guanidine F
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.